• Publications
  • Influence
How I treat the acquired von Willebrand syndrome.
The management of AVWS is reviewed with an overview on the currently available evidence and additional considerations for typical treatment situations, including treatment options including desmopressin, VWF-containing concentrates, intravenous immunoglobulin, plasmapheresis or recombinant factor VIIa.
Compensatory visual field training for patients with hemianopia after stroke
Improvements in detection of and reaction to visual stimuli without restitution of the visual field defect were maintained 8 months after training and activity of daily living skills also improved in all patients.
Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single‐centre cohort study
Early diagnosis of AVWS is difficult, due to lack of sensitivity of the tests used, and a substantial number of patients present with normal or increased test results, emphasizing the importance of multimer analysis in all patients with suspected AVWS.
Acquired hemophilia A: Updated review of evidence and treatment guidance
Acquired hemophilia A (AHA) is a rare disease resulting from autoantibodies (inhibitors) against endogenous factor VIII (FVIII) that leads to bleeding, which is often spontaneous and severe. AHA
Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A
N8‐GP is a recombinant factor VIII (FVIII) with a site‐directed glycoPEGylation for the purpose of half‐life prolongation.
Biosynthesis of Glycosylphosphatidylinositols in Mammals and Unicellular Microbes
Advances in the characterization of GPI biosynthesis in parasitic protozoa, yeast and mammalian cells are reviewed and first indications are that these differences could be exploited as targets in the design of novel pharmacotherapeutics that selectively inhibit GPI BIOSynthesis in unicellular microbes.
Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy
In conclusion, turoctocog alfa provides a new, safe and effective alternative for prophylaxis and treatment of bleeding episodes in patients with haemophilia A.
Diagnosis and treatment of acquired von Willebrand syndrome.
  • A. Tiede
  • Medicine
    Thrombosis research
  • 1 December 2012
AVWS should be considered in all patients with new-onset bleeding whenever laboratory findings suggest VWD, particularly in the presence of an AVWS-associated disorder, and treatment success will depend largely on the underlying pathogenesis of the disorder.
Bioequivalence between two serum‐free recombinant factor VIII preparations (N8 and ADVATE®) – an open‐label, sequential dosing pharmacokinetic study in patients with severe haemophilia A
N8 is bioequivalent to Advate® and N8 is well tolerated in the FHD trial, and there were no safety concerns in the study and no reports of inhibitor formation in the 72‐h period following exposure to a single N8 dose.
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.
Presenting FVIII and inhibitor concentration are potentially useful to tailor IST in AHA and are associated with a lower rate of complete remission and decreased survival.